19 September 2024 : Clinical Research
Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study
Sukunya Jirachaipitak1ABCDEF, Pramote Euasobhon1ABCDEFG*, Suthanee Cenpakdee1ABEF, Suratsawadee Wangnamthip1ABDE, Pranee Rushatamukayanunt1ABDEDOI: 10.12659/MSM.945612
Med Sci Monit 2024; 30:e945612
Figure 1 Flow diagram. Of 61 patients assessed for eligibility, 15 were excluded for loss to follow-up (n=4), age (n=3), and medical conditions (n=8). Of a total of 46 patients recruited into the study, 14 patients withdrew due to non-compliance with drug administration (n=1), oxcarbazepine allergies (n=5), or intolerable adverse events (n=8). Thirty-two patients were included in the final analysis of the study. Figure created using Microsoft Word (Version 2019, Microsoft Corporation).